AF
RANI icon

Allworth Financial’s Rani Therapeutics RANI Stock Holding History

Allworth Financial’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29K Hold
3,119
– – ﹤0.01% 4309
2025
Q4 		$4.21K Hold
3,119
– – ﹤0.01% 3815
2025
Q3 		$1.56K Hold
3,119
– – ﹤0.01% 4114
2025
Q2 		$1.6K Hold
3,119
– – ﹤0.01% 3801
2025
Q1 		$3.49K Hold
3,119
– – ﹤0.01% 2961
2024
Q4 		$4.65K Hold
3,119
– – ﹤0.01% 2799
2024
Q3 		$6.74K Hold
3,119
– – ﹤0.01% 2437
2024
Q2 		$9.61K Hold
3,119
– – ﹤0.01% 2234
2024
Q1 		$9.7K Hold
3,119
– – ﹤0.01% 2132
2023
Q4 		$10.4K Hold
3,119
– – ﹤0.01% 1968
2023
Q3 		$6.78K Sell
3,119
-3
-0.1% -$11 ﹤0.01% 1983
2023
Q2 		$12.9K Hold
3,122
– – ﹤0.01% 1779
2023
Q1 		$16.1K Buy
3,122
+3
+0.1% +$18 ﹤0.01% 1585
2022
Q4 		$18.4K Buy
+3,119
New +$22.8K ﹤0.01% 1403

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Allworth Financial's RANI Position: Q1 2026 in Review

Allworth Financial held its Rani Therapeutics (RANI) position steady in Q1 2026 at 3,119 shares worth $2.29K. The position accounts for ﹤0.01% of the portfolio, ranked #4309.

Allworth Financial first reported a position in RANI in Q4 2022 and has held it in 14 quarters since. The position peaked at $18.4K in Q4 2022. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Allworth Financial held 3,119 shares of Rani Therapeutics worth $2.29K as of Q1 2026.
  • Allworth Financial left its Rani Therapeutics share count unchanged in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4309 holding.
  • Allworth Financial first reported a position in Rani Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Allworth Financial's Rani Therapeutics position peaked at $18.4K in Q4 2022.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.